Golden Helix Hires New CEO; Positions Company for Growth in Translational Genomics
Bozeman, MT (May 2, 2013) — Golden Helix, a leading bioinformatic software and services company, today announced the hiring of new President and CEO, Dr. Andreas Scherer, as the company seeks to expand its operations in the rapidly evolving field of translational genomics.
Golden Helix’s efforts over the past decade have focused primarily on accelerating basic genetic research through easy-to-use bioinformatic solutions that empower scientists closest to the biology to analyze genomic data. Recent advances in next-generation sequencing, and the relative ease at which genomic data can now be generated, have put genomics at the forefront of patient diagnosis and care, creating greater opportunities for healthcare and life science organizations to effectively apply genomic knowledge to impact human health.
Golden Helix has been ramping up its operations to target translational genomics applications. The hiring of Dr. Scherer is a reflection of the company’s growth strategy and is expected to accelerate its effort in delivering more focused solutions for clinical genomics, pharmacogenomics, and advanced diagnostics.
Dr. Scherer, who began his executive career at AOL/Netscape, has managed global software and services businesses in excess of $100 million. He has a PhD in computer science and experience conducting research in DNA sequence analysis as well as intimate knowledge of the domestic and international life sciences market through his work in accelerating pharmaceutical R&D processes. Dr. Scherer is a recognized thought leader, business executive, and author of the prize-winning book, “Be Fast or Be Gone.”
“I am impressed by the strategic potential of Golden Helix as well as its ability to impact how genomics is used to diagnose, treat, and ultimately prevent human disease,” stated Dr. Scherer. “Golden Helix has long been at the forefront of delivering analytic solutions for genetic research. Now we are positioning the business to be a leader in translational genomics with tremendous opportunities for growth and positively impacting human health.”
Founder and former CEO, Dr. Christophe Lambert, has been the entrepreneurial force behind Golden Helix for 14 years. In his new role as Chairman, Dr. Lambert will continue to provide strategic oversight and industry thought leadership. This role allows him to pursue a number of strategic initiatives.
Dr. Lambert said, "I have known Andreas for almost a decade. I am impressed by his achievements in driving R&D productivity in the life sciences space. His background will be instrumental in positioning Golden Helix as the leading solution provider for translational genomics. I am tremendously excited to have him on board."
About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for 14 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With our solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 750 peer-reviewed publications.